Techlab Showcases Range of Rapid, Non-Invasive Intestinal and Infectious Disease Diagnostic Products
By LabMedica International staff writers Posted on 29 Sep 2021 |
TechLab Inc. (Blacksburg, VA, USA) showcased its range of rapid, non-invasive intestinal and infectious disease diagnostic products at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30.
The AACC Annual Scientific Meeting & Clinical Lab Expo is the largest global scientific conference and tradeshow in the field of laboratory medicine. TechLab develops, manufactures, and distributes rapid non-invasive intestinal diagnostics in the areas of intestinal inflammation, antibiotic associated diarrhea and parasitology. The company manufactures a variety of in vitro diagnostics for enteric diseases to help determine whether a patient has a disease caused by Helicobacter pylori, Clostridium difficile, protozoan parasites, foodborne illness, or IBD/IBS.
At AACC 2021, TechLab demonstrated its diagnostic tests for C. difficile, parasitology, intestinal inflammation, Shiga toxins and Campylobacter. TechLab showcased its TRI-COMBO PARASITE SCREEN test which is an enzyme immunoassay for the simultaneous qualitative detection of Giardia spp., Cryptosporidium spp., and/or E. histolytica antigen in human fecal specimens. The test is indicated for use as a screen for fecal specimens from patients with gastrointestinal illness including dysentery to aid in the diagnosis of enteric infection resulting from giardiasis, cryptosporidiosis or amebiasis. The TRI-COMBO PARASITE SCREEN test serves as a screen to rule out negative specimens and reduce the number of specimens that require additional follow-up testing. The test uses monoclonal and polyclonal antibodies to cell-surface antigens of Giardia, Cryptosporidium, and E. histolytica.
TechLab also highlighted the E. HISTOLYTICA QUIK CHEK test which is a rapid membrane enzyme immunoassay for the qualitative detection of adhesin from Entamoeba histolytica in a single use cassette. It is intended for use with human fecal specimens from patients with diarrhea or dysentery as an aid in the diagnosis of E. histolytica gastrointestinal infection. Also on display was the company’s GIARDIA/CRYPTOSPORIDIUM QUIK CHEK test which is a rapid membrane enzyme immunoassay for the simultaneous qualitative detection and differentiation of Giardia cyst antigen and Cryptosporidium oocyst antigen in a single test device. It is intended for use with human fecal specimens from patients with gastrointestinal symptoms to aid in the diagnosis of Giardia and/or Cryptosporidium gastrointestinal infection.
In addition, TechLab presented its C. DIFF QUIK CHEK COMPLETE test which is a rapid membrane enzyme immunoassay for the simultaneous detection of Clostridium difficile glutamate dehydrogenase antigen and toxins A and B in a single reaction well. The test is to be used as an aid in the diagnosis of C. difficile disease. The company also exhibited its SHIGA TOXIN QUIK CHEK test which is a rapid membrane enzyme immunoassay for the simultaneous qualitative detection and differentiation of Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) in a single test device. It is intended for use with human fecal samples from patients with gastrointestinal symptoms to aid in the diagnosis of disease caused by Shiga toxin producing Escherichia coli (STEC). It may be used with fecal specimens, or broth or plate cultures derived from fecal specimens.
Related Links:
TechLab Inc.
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms